Does Medicare Cover Zepbound in 2026? Weight Loss vs Sleep Apnea Coverage

Zepbound is at the heart of the largest Medicare drug coverage change in a generation, and the rules actually moved 2026. You are covered if you have one of two diagnoses, and depending on a pilot program that will be implemented this July.

There are two ways Medicare will cover Zepbound in 2026. Part D plans will cover the treatment of OSA except for the weight-loss exclusion, which means the first opened in December 2024, when the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The second starts July 1, 2026, with the Medicare GLP-1 Bridge pilot to pay for the Zepbound KwikPen for weight management instead, and copays limited to $50 a month, according to NPR.

Here is how each pathway works, who qualifies, and what you'll actually pay.

The Sleep Apnea Pathway: Covered Since 2024

The FDA's approval of Zepbound, a weight loss drug, in December 2024, made the Medicare equation different; the statutory exclusion only prevents the use of weight loss drugs, not those that treat a diagnosed medical condition. OSAS is considered just that.

You must have a moderate-to-severe OSA diagnosis from a sleep study, have obesity, and have Zepbound included on your Part D or Medicare Advantage plan's formulary for the indication. It was implemented gradually over a period of years until 2025, and sometimes more slowly than other plans, so be sure to verify your specific plan. Usually the sleep study and BMI documentation are needed along with sometimes evidence of CPAP usage or intolerance.

The Weight-Loss Pathway: The Medicare GLP-1 Bridge Pilot

This is the historic change. Until the pricing agreement in November 2025, the Medicare law prohibited weight-loss medications, and the final regulations for 2026 maintained this prohibition, but the deal with the administration, Eli Lilly, and Novo Nordisk provided a demonstration program to get around the prohibition. The Medicare GLP-1 Bridge was finalized after a previous pilot design failed to make it through when insurers balked, STAT News reports.

The Bridge runs July 1, 2026 through December 31, 2027. It includes Zepbound KwikPen, Wegovy (pill form), injectable Wegovy, and the new oral pill Foundayo. To qualify you must be enrolled in a Part D plan and have a BMI of 27 or higher with a qualifying condition such as heart disease or prediabetes. If the prescriber certifies having met the criteria at the beginning of therapy, a Zepbound patient may qualify even if their BMI has dropped since therapy began. You won't pay a copay more than $50 per month, and Medicare will cover the negotiated $245 monthly price.

What Zepbound Costs on Medicare in 2026

In both scenarios, the price Medicare receives has been determined at $245/month plus a $50 cap on the beneficiary cost (from a $1,086 list price). The regular Part D benefits are also included: The $615 Part D deductible and the $2,100 out-of-pocket cap on all covered drugs.

As long as you don't fit into either of the above groups, Lilly's self-pay channel is you! LillyDirect vials cost between $349 and $499 per month and KwikPens are priced between $399 and $449 — tirzepatide will be available at the federal TrumpRx channel at close to $346 starting to expand in 2026.

How to Get Zepbound Covered: Step by Step

The OSA route requires the sleep study first, otherwise, nothing moves. You should then submit prior authorization with study, BMI, and CPAP history to your doctor. For the Bridge route, confirm the enrollment in Part D prior to the close of enrollment; document BMI and qualifying condition with prescriber before July; submit enrollment as soon as the program opens as demonstration programs may be limited in enrollment.

If you are denied on either course? Appeals move at a rapid pace: Redetermitation within 7 days for conventional appeals or 72 hours for expedited appeals. Most OSA denials are resolved through prescriber attestation and complete sleep-study documentation resolves most Bridge denials.